Abstract
Prolactinomas are the most frequent pituitary tumors and their frequency varies with age and sex, occurring most frequently in females between 20–50 yr-old. In men, hyperprolactinaemia is often present for many years without symptoms, as generally the most important symptoms are the decrease in libido and/or sexual potency both underestimated by the majority of the patients. Prolactin (PRL) plays a role in the process of spermatogenesis, and normal serum PRL levels are required for normal testicular function. On the other hand, hyperprolactinaemia has multiple negative effects on the gonadal axis. As a consequences hyperprolactinemic males show alteration of sexual potency and seminal fluid quality. Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 1998;352:1455–1461.
Colao A, Di Sarno A, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 2003;148(3):325–331.
Vance ML, Thorner MO. Prolactin: hyperprolactinemic syndromes and management. In: DeGroot LJ (ed.), Textbook of Endocrinology, 2nd edition. Philadelphia, London, Toronto, Mexico City, Rio de Janerio, Sydney, Tokyo, Hong Kong:WB Saunders Company, 1989, pp. 408–418.
Calle-Rodrigue RD, Giannini C, Scheithauer BW, et al. Prolactinomas in male and female patients: A comparative clinicopathologic study. Mayo Clin Proc. 1998;73:1046–52.
Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study. J Clin Endocrinol Metab 1997;82:2102–2107.
Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;84(7):2518–2522.
Molitch ME: Prolactinoma. In: Melmed S (ed.), The Pituitary, Boston: Blackwell Scientific, 1995, pp. 443–477.
Leonard MP, Nickel CJ, Marales A. Hyperprolactinemia and impotence: Why, when and how to investigate. J Urol 1989;142(4):992–994.
Colao A, Vitale G, Cappabianca P, et al. Outcome of Cabergoline treatment in men with prolactinoma: Effects of a 24-months treatment on prolactin levels, tumor mass, recovery of pituitari function, and semen analysis. J Clin Endocrinol Metab 2004;89:1704–1711.
Biller BMK, Molitch M, Vance ML, et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81(6):2338–2343.
Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998;19(3):225–268.
Hondo E, Kurohmaru M, Sakai S, Ogawa K, Hayashi Y. Prolactin receptor expression in rat spermatogenic cells. Biol Reprod 1995;52(6):1284–1290.
Winters SJ. Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J Androl 1991;12(3):185–190.
Manandhar MS, Thomas JA. Effect of prolactin on the metabolism of androgens by the rat ventral prostate gland in vitro. Invest Urol 1976;14(1):20–22.
Bartke A. Male hamster endocrinology. In: Siegel, H (ed.), The hamster, Reproduction and behaviour New York: Plenum Press, 1985, pp. 73–98.
Colao A, De Rosa M, Sarnacchiaro F, et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur J Endocrinol 1996;135:548–552.
De Rosa M, Colao A, Di Sarno A, et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol. 1998;138:286–293.
De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004;89:621–625.
Costello LC, Franklin RB. Effect of prolactin on the prostate. Prostate. 1994;24(3):162–166.
Colao A, Vitale G, Di Sarno A, et al. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 2004;89(6):2770–2775.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ciccarelli, A., Guerra, E., De Rosa, M. et al. PRL Secreting Adenomas in Male Patients. Pituitary 8, 39–42 (2005). https://doi.org/10.1007/s11102-005-5084-3
Issue Date:
DOI: https://doi.org/10.1007/s11102-005-5084-3